David Goldfarb, MD Appointed Clinical Chief in the Division of Nephrology

Medicine Department Chair and Nephrology Division Director Announce Appointment

January 31, 2007

Dear Colleagues,

Dr. Edward Y. Skolnik and I are pleased to announce the appointment of Dr. David Goldfarb to Clinical Chief in the Division of Nephrology. In this new position, Dr. Goldfarb will help in overseeing the clinical direction of Nephrology services throughout NYU Medical Center. In addition, Dr. Goldfarb will work to further develop and improve clinical research within the Division of Nephrology, working closely with Dr. Skolnik, the Norman S. Wikler Professor of Medicine and Director of the Division.

Dr. Goldfarb is currently Professor of Medicine and Physiology and Neuroscience at NYU and Chief of the Nephrology Section at the New York campus of the New York Harbor Health Care Veterans Affairs System. He received a BA from Yale in 1977 and his MD from Yale School of Medicine in 1981. He trained in internal medicine at NYU in 1981-1984 and served as chief resident at the VA in 1984-1985. He then completed his training in nephrology at NYU from 1985-1987. He has worked full-time in the nephrology section at the New York VA and in the NYU nephrology division since 1987.

Dr. Goldfarb is internationally recognized for his studies on kidney stones. Dr. Goldfarb started the NYU Kidney Stone Prevention Program where he oversees the clinical care of kidney stone-formers and performs clinical research in kidney stone treatment and prevention. He has authored many articles and book chapters on nephrolithiasis and is invited frequently to speak on this subject at both national and international meetings. Dr. Goldfarb was among the first researchers to demonstrate genetic linkages of kidney stones in the general population. His current work includes the effects of intestinal bacteria on urinary oxalate excretion, the effects of foods and beverages on urine chemistry, and treatment of cystinuria. Dr. Goldfarb also is collaborating with researchers in Iceland and Children’s Hospital of Pennsylvania to find other genetic causes of kidney stones. In addition to his studies on kidney stones, Dr. Goldfarb is a member of the Executive Committees of three national VA Cooperative Studies Program trials, including the recently concluded “Homocysteine Study,” a trial of high-dose folic acid for patients with kidney disease.

Dr. Goldfarb also is an outstanding teacher. He was voted “Distinguished Teacher in the Basic Sciences” by the NYU Class of 2006 for teaching renal physiology, and “Teacher of the Year” by the Class of 2005 for his directing the nephrology section of the second-year pathophysiology course. He also is frequently voted “best teacher” in the Nephrology Section by the Renal Fellows. Please join us in welcoming Dr. Goldfarb to this new position. 

Sincerely yours,

Martin J. Blaser, M.D.
Frederick H. King Professor of Internal Medicine
Chair, Department of Medicine

Edward Y. Skolnik, M.D.
Norman S. Wikler Professor of Medicine
Division Director, Nephrology